Novel antimicrobials targeting MDR pathogens from animal microbial symbionts

针对动物微生物共生体中的耐多药病原体的新型抗菌药物

基本信息

批准号：
10592380
负责人：
David R Andes
金额：
$ 595.5万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10592380
关键词：
Address Anabolism Animals Anti-Infective Agents Antibiotics Antimicrobial Resistance Bacteria Biological Biological Assay Chemicals Computational Biology Culture Techniques Development Drug resistance Ecology Environment Epidemic Genomics Goals Health Human In Vitro Invertebrates Investigation Lead Libraries Medicine Methods Microbe Microbial Genome Sequencing Mining Minority Natural Compound Natural Products Natural Products Chemistry Pathogenesis Pathway interactions Pharmaceutical Preparations Production Property Public Health Research Resistance Resources Safety Series Soil Source Streptomyces Symbiosis Taxon Techniques Technology Testing Therapeutic Wisconsin Work antimicrobial antimicrobial drug antimicrobial resistant infection clinical development combat drug development drug discovery drug resistant bacteria drug resistant pathogen effective therapy fungus in vivo industry partner innovation insight marine metabolomics microbial microbiome multi-drug resistant pathogen multidisciplinary natural antimicrobial next generation novel novel therapeutics pathogen pathogenic bacteria pathogenic fungus pre-clinical preclinical study scaffold secondary metabolite small molecule success symbiont theories

项目摘要

Project Summary The discovery of new antimicrobials has failed to keep pace with the emergence of antimicrobial-resistant infections, threatening public health. The overarching goal of the Wisconsin Antimicrobial Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial resistance crisis. Based upon our preliminary investigations using interdisciplinary, cutting-edge approaches, we hypothesize that natural products from animal-microbe symbioses represent a new paradigm in antimicrobial drug discovery. The Center proposes innovative conceptual and technical advances to overcome the critical bottlenecks of traditional antimicrobial discovery to deliver therapeutic countermeasures for the drug-resistance epidemic. Relevance There is an ever-present and growing need to find novel, effective therapies for emerging resistant pathogens that are becoming an increasing threat to the public health. The goals of the Center are to discover new antimicrobial drugs. Our collaborative effort focuses on high-value natural products produced by under- explored sources of biological and chemical diversity.

项目概要新抗菌药物的发现未能跟上抗菌药物耐药性出现的步伐感染，威胁公众健康。威斯康星州抗菌药物发现和开发中心致力于制定治疗对策以应对抗菌素耐药性危机。根据我们使用跨学科、前沿方法的初步调查，我们假设来自动物-微生物共生的天然产物代表了抗菌药物发现的新范例。这中心提出创新的概念和技术进步，以克服传统的关键瓶颈抗菌药物的发现可为耐药性流行病提供治疗对策。关联对于新出现的耐药病原体，寻找新的、有效的疗法的需求始终存在且不断增长这些正在成为对公众健康日益严重的威胁。该中心的目标是发现新的抗菌药物。我们的合作重点是通过以下方式生产的高价值天然产品：探索生物和化学多样性的来源。